ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sinovac Biotech and Sinopharm side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Sinovac BiotechSinopharm
studies on the registry16395
open to participants now3618
phase 3 studies under way177
reach primary completion within a year155
programswith a study of their own in two years3212

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSinovac BiotechSinopharm
Phase 113%50%
Phase 228%50%
Phase 334%00%
Approved, new studies

Sinovac Biotech: 8 of its 32 programs at approved, new studies

  1. experimental vaccineapproved, new study
  2. Chickenpox Vaccineapproved, new study
  3. EV71approved, new study
  4. Poliovirus Vaccine, Inactivatedapproved, new study
  5. 1wIPV+2sIPVapproved, new study

and 3 more — sign in to see them all

25%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Sinovac Biotech9 readouts · 7 phase 3

Sinovac Biotech, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. experimental vaccineapproved, new study · Nov 0 · NCT07505888

Sinovac Biotech, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Cell-based Trivalent Split Influenza Virus Vaccine (cTIV)phase 1 · Dec 0 · NCT07889193
  2. Rabies Vaccine (Serum-free Vero Cell), Freeze-driedphase 3 · Dec 30 · NCT07055295

Sinovac Biotech, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. EV71approved, new study · Jan 9 · NCT07793175
  2. Rabies vaccinephase 3 · Jan 30 · NCT07055893

Sinovac Biotech, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Anflu®approved, new study · Feb 0 · NCT07832201

Sinovac Biotech, Mar ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Sinovac PCV13phase 3 · Mar 0 · NCT07832500
  2. SNA02-48phase 3 · Mar 31 · NCT07633119
·····

Sinovac Biotech, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL)phase 3 · Sep 15 · NCT07793227
·
Sinopharm2 readouts · 0 phase 3···

Sinopharm, Feb ’27: 1 program whose next study reaches primary completion

  1. MVA-SIBP low dosephase 2 · Feb 28 · NCT07253675

Sinopharm, Mar ’27: 1 program whose next study reaches primary completion

  1. SIBP-A16 injectionphase 2 · Mar 31 · NCT07363837
·······
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Sinovac Biotech

New programs 3

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Sinopharm

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.

ConditionSinovac BiotechSinopharm
Herpes Zosterboth · compare here

Sinovac Biotech in Herpes Zoster: 4 programs

  1. Active-controlled vaccine Aphase 2
  2. Active-controlled vaccine Bphase 2
  3. experimental vaccineapproved, new study
  4. Chickenpox Vaccineapproved, new study

Their studies: Sinovac Biotech’s studies of Herpes Zoster in search

Influenza, Humanboth · compare here

Sinopharm in Influenza, Human: 1 program

  1. Influenza virus split vaccine (0.7mL/vial)phase 2

Their studies: Sinopharm’s studies of Influenza, Human in search

Rabiesboth · compare here
Tetanusboth · compare here

Sinovac Biotech in Tetanus: 3 programs

  1. SNA02-48phase 3
  2. Tetanus Toxoidphase 2
  3. Poliovirus Vaccine, Inactivatedapproved, new study

Their studies: Sinovac Biotech’s studies of Tetanus in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Sinovac Biotech 21 of 32 · Sinopharm 3 of 12 programs. Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.